[{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"676a91c9-2aba-4008-872e-5a9b996188c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791083","created_at":"2025-02-25T18:40:00.939Z","updated_at":"2025-02-25T18:40:00.939Z","phase":"Phase 2","brief_title":"Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","source_id_and_acronym":"NCT06791083","lead_sponsor":"First Affiliated Hospital of Fujian Medical University","biomarkers":" CD8 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-01-24"},{"id":"9a52755e-dbe3-4f7e-9944-bdfa5fefb944","acronym":"","url":"https://clinicaltrials.gov/study/NCT05085548","created_at":"2025-02-25T20:19:18.640Z","updated_at":"2025-02-25T20:19:18.640Z","phase":"Phase 1","brief_title":"ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies","source_id_and_acronym":"NCT05085548","lead_sponsor":"ProDa BioTech, LLC","biomarkers":" CD31 • PECAM1 • PKM","pipe":"","alterations":" ","tags":["CD31 • PECAM1 • PKM"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-15"},{"id":"e31b42b2-f7e8-44ab-9de8-d823f2ad231d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091750","created_at":"2025-02-26T07:16:40.448Z","updated_at":"2025-02-26T07:16:40.448Z","phase":"Phase 2","brief_title":"Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma","source_id_and_acronym":"NCT04091750","lead_sponsor":"Georgetown University","biomarkers":" TMB • CD31 • PECAM1","pipe":"","alterations":" ","tags":["TMB • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 03/02/2020","start_date":" 03/02/2020","primary_txt":" Primary completion: 08/08/2023","primary_completion_date":" 08/08/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-11-27"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"f60c75c5-5918-4436-a5b9-e1d595fd18d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03149081","created_at":"2021-01-18T15:31:13.961Z","updated_at":"2024-07-02T16:35:07.015Z","phase":"Phase 1","brief_title":"A \"Window Trial\" on Boswellia for Breast Cancer Primary Tumors","source_id_and_acronym":"NCT03149081","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 08/31/2017","start_date":" 08/31/2017","primary_txt":" Primary completion: 04/29/2024","primary_completion_date":" 04/29/2024","study_txt":" Completion: 04/29/2024","study_completion_date":" 04/29/2024","last_update_posted":"2024-04-30"},{"id":"42bddf58-5af8-4513-90ad-a3d09c1a565b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05585476","created_at":"2022-10-18T14:57:23.344Z","updated_at":"2024-07-02T16:35:08.023Z","phase":"","brief_title":"A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.","source_id_and_acronym":"NCT05585476","lead_sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-23"},{"id":"f1cfe322-7c0f-4270-b499-e5b443eefa43","acronym":"CARLOTTA01","url":"https://clinicaltrials.gov/study/NCT05836896","created_at":"2023-05-01T14:03:57.086Z","updated_at":"2024-07-02T16:35:18.546Z","phase":"Phase 1","brief_title":"A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","source_id_and_acronym":"NCT05836896 - CARLOTTA01","lead_sponsor":"Technische Universität Dresden","biomarkers":" CD31 • SLAMF7","pipe":" | ","alterations":" CD38 positive","tags":["CD31 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDC-CAR-BCMA001"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-20"},{"id":"00dae94b-2c6c-41e1-8271-7129d46282fb","acronym":"SIGNAL 2","url":"https://clinicaltrials.gov/study/NCT02212860","created_at":"2021-01-18T10:21:56.618Z","updated_at":"2024-07-02T16:35:25.466Z","phase":"","brief_title":"Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy","source_id_and_acronym":"NCT02212860 - SIGNAL 2","lead_sponsor":"Lawson Health Research Institute","biomarkers":" ER • CD8 • HIF1A • CXCL12 • CD4 • CASP3 • VIM • CD31 • PECAM1","pipe":" | ","alterations":" ER positive","tags":["ER • CD8 • HIF1A • CXCL12 • CD4 • CASP3 • VIM • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 139","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-12-22"},{"id":"3fbd9f5e-b663-46f9-bdb6-fab9395d1437","acronym":"","url":"https://clinicaltrials.gov/study/NCT06152263","created_at":"2023-12-14T16:17:34.790Z","updated_at":"2024-07-02T16:35:26.261Z","phase":"","brief_title":"LCI in Chronic Atrophic Gastritis and Early Gastric Cancer","source_id_and_acronym":"NCT06152263","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-12-14"},{"id":"c7b7bd00-27a7-4b16-a957-1357269d100b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03422731","created_at":"2021-01-18T16:53:37.171Z","updated_at":"2024-07-02T16:35:29.442Z","phase":"Phase 1","brief_title":"Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy","source_id_and_acronym":"NCT03422731","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD34 • CD31 • PECAM1"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 02/15/2018","start_date":" 02/15/2018","primary_txt":" Primary completion: 11/06/2024","primary_completion_date":" 11/06/2024","study_txt":" Completion: 11/06/2024","study_completion_date":" 11/06/2024","last_update_posted":"2023-11-13"},{"id":"09b806b7-5ada-4ec4-bf5b-2c8ce1a24629","acronym":"BACCARAT","url":"https://clinicaltrials.gov/study/NCT02605512","created_at":"2022-06-04T15:45:36.960Z","updated_at":"2024-07-02T16:35:29.944Z","phase":"","brief_title":"BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study","source_id_and_acronym":"NCT02605512 - BACCARAT","lead_sponsor":"Sophie JACOB","biomarkers":" IL6 • CD14 • MIR34A • IL18 • CD31 • MIR17 • MIR182 • MIR18A • PECAM1 • CRP • ITGA2B • MIR140 • MIR145 • MIR150 • MIR22 • MIR423","pipe":"","alterations":" ","tags":["IL6 • CD14 • MIR34A • IL18 • CD31 • MIR17 • MIR182 • MIR18A • PECAM1 • CRP • ITGA2B • MIR140 • MIR145 • MIR150 • MIR22 • MIR423"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2023-11-08"},{"id":"94c5955f-8283-4ecf-ba19-c80d9a7540f8","acronym":"TAR-200-101","url":"https://clinicaltrials.gov/study/NCT02722538","created_at":"2021-01-18T13:19:14.253Z","updated_at":"2024-07-02T16:35:36.803Z","phase":"Phase 1b","brief_title":"Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02722538 - TAR-200-101","lead_sponsor":"Taris Biomedical LLC","biomarkers":" PD-L1 • CD8 • CD4 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD4 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Inlexzo (gemcitabine intravesical system)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 05/02/2019","primary_completion_date":" 05/02/2019","study_txt":" Completion: 05/02/2019","study_completion_date":" 05/02/2019","last_update_posted":"2023-09-18"},{"id":"ef958c21-2bd2-4580-9476-499c60150559","acronym":"VICKI","url":"https://clinicaltrials.gov/study/NCT06020651","created_at":"2023-08-31T13:09:53.820Z","updated_at":"2024-07-02T16:35:38.540Z","phase":"","brief_title":"Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside","source_id_and_acronym":"NCT06020651 - VICKI","lead_sponsor":"Institut Mutualiste Montsouris","biomarkers":" VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B","pipe":"","alterations":" ","tags":["VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-31"},{"id":"ebea8369-a309-4f15-9f25-3c7393207af5","acronym":"PRODIGYN","url":"https://clinicaltrials.gov/study/NCT05855941","created_at":"2023-05-12T17:04:42.348Z","updated_at":"2024-07-02T16:35:40.129Z","phase":"","brief_title":"Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)","source_id_and_acronym":"NCT05855941 - PRODIGYN","lead_sponsor":"Region Västerbotten","biomarkers":" POLE • BRCA • CD31 • PECAM1","pipe":" | ","alterations":" POLE mutation • BRCA mutation","tags":["POLE • BRCA • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 05/01/2032","primary_completion_date":" 05/01/2032","study_txt":" Completion: 05/01/2032","study_completion_date":" 05/01/2032","last_update_posted":"2023-08-14"},{"id":"576ff15e-7a07-4123-9e2a-6f4a1fed07d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00813423","created_at":"2021-01-18T03:05:24.899Z","updated_at":"2024-07-02T16:35:41.219Z","phase":"Phase 1","brief_title":"Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy","source_id_and_acronym":"NCT00813423","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD31 • ENG • PECAM1 • BECN1","pipe":"","alterations":" ","tags":["CD31 • ENG • PECAM1 • BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2010","start_date":" 02/19/2010","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-02"},{"id":"c70be74b-2caf-4912-96ba-c804e6129925","acronym":"NeoART","url":"https://clinicaltrials.gov/study/NCT02633098","created_at":"2021-01-18T12:48:25.777Z","updated_at":"2024-07-02T16:36:02.617Z","phase":"Phase 2","brief_title":"A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","source_id_and_acronym":"NCT02633098 - NeoART","lead_sponsor":"St George's, University of London","biomarkers":" KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • MYC expression • CCND1 expression","tags":["KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • MYC expression • CCND1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/26/2017","start_date":" 04/26/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2022-10-12"},{"id":"5363ddba-ce3b-4487-8a21-7cccbee4cdbe","acronym":"INTRANS","url":"https://clinicaltrials.gov/study/NCT03754140","created_at":"2021-06-15T21:52:36.260Z","updated_at":"2024-07-02T16:36:07.298Z","phase":"Phase 2","brief_title":"Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases","source_id_and_acronym":"NCT03754140 - INTRANS","lead_sponsor":"Melanoma Institute Australia","biomarkers":" CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-14"},{"id":"9f7355a9-0af0-4782-89ec-054c6b9f75af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02897050","created_at":"2021-01-18T14:13:00.270Z","updated_at":"2024-07-02T16:36:11.800Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","source_id_and_acronym":"NCT02897050","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • ER • PGR • CD31 • PECAM1","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • capecitabine • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 170","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-04-20"},{"id":"859d4daf-1a31-438b-8dbf-f8ed4a89b5e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02357836","created_at":"2021-05-03T19:53:14.312Z","updated_at":"2024-07-02T16:36:30.803Z","phase":"Phase 1","brief_title":"Neoadjuvant Itraconazole in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02357836","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1","pipe":" | ","alterations":" MTOR mutation","tags":["CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2021-05-03"},{"id":"21dc6bdb-6650-46b2-a9db-1be405cd42e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00979810","created_at":"2021-01-18T03:49:23.259Z","updated_at":"2024-07-02T16:36:37.231Z","phase":"","brief_title":"Image-Guided Stereotactic Biopsy of High Grade Gliomas","source_id_and_acronym":"NCT00979810","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/16/2009","start_date":" 09/16/2009","primary_txt":" Primary completion: 02/24/2020","primary_completion_date":" 02/24/2020","study_txt":" Completion: 02/24/2020","study_completion_date":" 02/24/2020","last_update_posted":"2020-12-17"},{"id":"faea8229-90b5-43f1-829f-e4b604965cd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02720367","created_at":"2021-01-18T13:18:32.264Z","updated_at":"2024-07-02T16:36:48.991Z","phase":"Phase 1b","brief_title":"Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02720367","lead_sponsor":"Taris Biomedical LLC","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Inlexzo (gemcitabine intravesical system)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-03-10"}]